Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Avdoralimab · IPH-5401, NN-8210

Monoclonal antibody · Antagonist of C5a receptor (C5AR1) · developed by Innate Pharma

Phase 2 Most advanced trial (none active)
IPHA Developer
2 Registered trials

What is Avdoralimab?

Avdoralimab is a human monoclonal antibody that binds and blocks the C5a receptor (C5aR) on subsets of myeloid-derived suppressor cells and neutrophils, preventing C5a from activating these cells. It is being studied in advanced solid tumors and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
IPH-5401, NN-8210, NNC-0215-0384
Drug type
Monoclonal antibody
Targets
C5a receptor (C5AR1)
Mechanism
Antagonist of C5a receptor (C5AR1)
Pathways
complement C5a signaling, MDSC and neutrophil activation and accumulation in the tumor microenvironment, T- and NK cell activation
Therapy area
Infectious disease, Oncology
Developer
Innate Pharma (IPHA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
DW4CE8MKS9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04371367 Phase 2 COVID Completed IPHA
NCT03665129 Phase 1 Advanced Solid Tumors Terminated IPHA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsCOVID

More from Innate Pharma

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.

Follow IPHA, the company behind Avdoralimab

See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IPHA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.